恩替卡韦治疗慢性乙型肝炎患者血清MIF、IL-17和IL-10的变化及临床意义

The changes and clinical value of MIF,IL-17 and IL-10 in serum of chronic hepatitis B treated with entecavir

目的探讨恩替卡韦治疗慢性乙型肝炎患者血清巨噬细胞移动抑制因子(MIF)、白细胞介素-17(IL-17)及白细胞介素-10(IL-10)的变化及其与肝脏炎性反应的关系。方法选择36例慢性乙型肝炎患者作为实验组,另选12名健康人作为对照组。采用ELISA法测定血清MIF、IL-17和IL-10的含量,同时检测ALT、HBV DNA和HBV标志物。结果实验组ALT及HBV DNA在第4周开始出现明显下降,MIF、IL-17的含量在第4周开始出现明显升高,其后逐渐下降,而IL-10的含量在第12周时明显下降,其后逐渐升高,与对照组比较,差异有统计学意义(P<0.05)。结论恩替卡韦在有效抑制HBV的同时,还能够调节MIF、IL-17和IL-10的平衡,减轻肝脏的炎性反应。

Objective To discuss the relationship between the changes of MIF,IL-17 and IL-10 in serum and liver inflammation during treatment with Baraclude in chronic hepatitis B patients.Methods Thirty-six chronic hepatitis B patients were identified as the experiment group,1 2 normal subj ects as the control group.MIF,IL-1 7 and IL-1 0 levels were detected by double antibody sandwich enzyme-linked immunosorbent assay （ELISA）in peripheral serum of two groups,and levels of serum ALT,HBV DNA and HBV-M in the experiment group were evaluated.Results Levels of MIF and IL-1 7 of the experiment group increased significantly in the 4th week,then decreased gradually,along with levels of ALT and HBV DNA which reduced significantly from the 4th week.Level of IL-10 decreased in the 12th week and then increased gradually.There were significant differences in the changes of MIF,IL-1 7 and IL-1 0 of the experiment group, compared to the control group（P〈0.05）.Conclusion In addition to suppress HBV effectively,Baraclude may adjust the balance of MIF,IL-17 and IL-10,and alleviate liver inflammation.